Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking.
Read the full report on Asianet Newsable
Story file
- Section
- Health
- Topics
- Health alerts
- First reported by
- Asianet Newsable
- Reporter
- stocktwits inc
- Published
- Saturday, 24 October 2026, 6:15 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
